Art. -Nr.: HY-70072

D609

8 Cited Publications

Kundenbewertung

Based on 8 publication(s) in Google Scholar

D609, an antitumoural xanthate, is a specific and competitive phosphatidyl choline-specific phospholipase C (PC-PLC) inhibitor with a K_i of 6.4 μM. D609 is an antioxidative protector and has antiviral and anti-inflammatory activity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.0%
CAS. Nr.: 83373-60-8
Formel: C₁₁H₁₅KOS₂
Molecular Weight:266.46

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

D609 Chemical Structure

CAS. Nr.: 83373-60-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (8)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Ki: 6.4 μM (PC-PLC)

Alle Phospholipase Isoform-spezifische Produkte anzeigen :

In Vitro

D609 (100 μM; for 2 h) significantly attenuats the proliferation of various cell lines^[2].
D609 (50, 100 and 200 μM; for 2 h) results in caspase-3 activation with 200 μM and causes no detectable cleavage with 50, 100 μM^[2].
D609 (100 μM; for 2 h) significantly inhibits BrdU incorporation in BV-2 microglia and causes accumulation of cells in G1 phase with decreased number of cells in the S phase^[2].
D609 (100 μM; for 2 h and cultured for an additional 2 h or 22 h without D609) increases ceramide levels, up-regulates p21 expression and causes a decreases in phospho-Rb^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[2]

Cell Line:

RAW 264.7 macrophages, N9 and BV-2 microglia, and DITNC1 astrocytes
Concentration:

100 μM
Incubation Time:

For 2 hours
Result:

Significantly attenuated the proliferation of RAW 264.7 macrophages, N9 and BV-2 microglia, and DITNC1 astrocytes, without affecting cell viability.

Apoptosis Analysis^[2]

Cell Line:

BV-2 cells
Concentration:

50, 100 and 200 μM
Incubation Time:

For 2 hours
Result:

Activated caspase-3 in a dose- and time-dependent manner.

Cell Cycle Analysis^[2]

Cell Line:

BV-2 cells
Concentration:

100 μM
Incubation Time:

For 2 hours
Result:

Significantly inhibited BrdU incorporation in BV-2 microglia and caused accumulation of cells in G1 phase with decreased number of cells in the S phase.

Western Blot Analysis^[2]

Cell Line:

BV-2 cells
Concentration:

100 μM
Incubation Time:

For 2 hours
Result:

Increased ceramide levels, up-regulated p21 expression and causes a decreased in phospho-Rb.

In Vivo

D609 (2.5, 10 mg/kg/day; ip; for 6 weeks) inhibits the progression of preexisting atherosclerotic lesions in apoE^-/- mice and changes the lesion composition into a more stable phenotype^[3].
D609 (50 mg/kg; ip; single dose) for 30 min before intratracheal administration of LPS (3 mg/kg) prevents the development of LPS-induced pulmonary hypertension in adult male Wistar rats^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

26-week-old apoE^−/− and C57BL/6 WT mice^[3]
Dosage:

2.5, 10 mg/kg
Administration:

IP; per day for 6 weeks
Result:

Inhibited the progression of preexisting atherosclerotic lesions in apoE^−/− mice and changed the lesion composition into a more stable phenotype.
Significantly decreased the aortic endothelial expression of the vascular cell adhesion molecule-1 and the intercellular adhesion molecule-1.

Chemical Information

CAS. Nr. 83373-60-8
Appearance Solid
Molecular Weight 266.46
Formel C₁₁H₁₅KOS₂
Color White to off-white
SMILES

S=C(OC1C2C3CCCC3C(C1)C2)S[K]
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (8)

All WBBio/Physico-chemical AssayCell Imaging/Staining

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

Male-Biased Gut Microbiome and Metabolites Aggravate Colorectal Cancer Development. [Abstract]

2023 Sep;10(25):e2206238. PMID: 37400423
Int J Mol Sci

Direct and Indirect Downstream Pathways That Regulate Repulsive Guidance Effects of FGF3 on Developing Thalamocortical Axons. [Abstract]

2025 Jul 30;26(15):7361. PMID: 40806490
J Physiol Biochem

D609 inhibition of phosphatidylcholine-specific phospholipase C attenuates prolonged insulin stimulation-mediated GLUT4 downregulation in 3T3-L1 adipocytes. [Abstract]

2022 May;78(2):355-363. PMID: 35048323

D609 purchased from MedChemExpress. Usage Cited in: J Physiol Biochem. 2022 May;78(2):355-363. [Abstract]

D609 (0, 50, 100, 200 μM; 30 min; insulin (500 nM) for 4 h) showed a weakened GLUT4 deficit in 3T3-L1 cells.

D609 purchased from MedChemExpress. Usage Cited in: J Physiol Biochem. 2022 May;78(2):355-363. [Abstract]

D609 (200 μM; 30 min; insulin (500 nM) for 4 h) showed an inhibitory effect on PC-PLC activity in 3T3-L1 cells in the membranes (a) and no effect in total lysate (b).
Bioorg Med Chem

Discovery, synthesis and biological evaluation of 2-(4-(N-phenethylsulfamoyl)phenoxy)acetamides (SAPAs) as novel sphingomyelin synthase 1 inhibitors. [Abstract]

2015 Sep 15;23(18):6173-84. PMID: 26314925
Traffic

Trafficking of Acetyl-C16-Ceramide-NBD with Long-Term Stability and No Cytotoxicity into the Golgi Complex. [Abstract]

2015 May;16(5):476-92. PMID: 25615589
Thromb J

The role of Sphingomyelin synthase 2 (SMS2) in platelet activation and its clinical significance. [Abstract]

2021 Apr 28;19(1):27. PMID: 33910580

D609 purchased from MedChemExpress. Usage Cited in: Thromb J. 2021 Apr 28;19(1):27. [Abstract]

D609 (0, 10, 100 μM) weakened PLCγ/PI3K/Akt phosphorylation in human platelets after stimulated by thrombin (0.03 U/mL) in a dose-dependent manner.

D609 purchased from MedChemExpress. Usage Cited in: Thromb J. 2021 Apr 28;19(1):27. [Abstract]

D609 (0, 10, 30, 100 μM) started to show an inhibitory effect on aggregation at a concentration of 10 µM. The aggregation rate was further reduced by an increase in concentration to 30 µM; when the concentration was increased to 100 µM, thrombin- and collagen-induced platelet aggregation were almost completely blocked.

D609 purchased from MedChemExpress. Usage Cited in: Thromb J. 2021 Apr 28;19(1):27. [Abstract]

D609 (100 μM) significantly inhibited platelet spreading.

D609 purchased from MedChemExpress. Usage Cited in: Thromb J. 2021 Apr 28;19(1):27. [Abstract]

D609 (10, 100 μM; 0, 30, 40, 50, 60 min) had no significant effect on clot retraction at low-dose D609 (10 µM), high-dose D609 (100 µM) remarkably suppressed clot retraction.
Curr Eye Res

Kisspeptin Suppresses the Growth of Primary Pterygial Cells via Inhibiting Chemokine (C-X-C Motif) Ligands in Microenvironment. [Abstract]

2025 Jun 24:1-9. PMID: 40555256
Patent

US20230050888A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (375.29 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 2 mg/mL (7.51 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.7529 mL

18.7645 mL

37.5291 mL

5 mM

0.7506 mL

3.7529 mL

7.5058 mL

10 mM

0.3753 mL

1.8765 mL

3.7529 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3 mg/mL (11.26 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 3 mg/mL (11.26 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3 mg/mL (11.26 mM); Clear solution

This protocol yields a clear solution of ≥ 3 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 25 mg/mL (93.82 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. E Amtmann, et al. The antiviral, antitumoural xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res. 1996;22(6):287-94. [Content Brief]

[2]. Gusain A, et al. Anti-proliferative effects of tricyclodecan-9-yl-xanthogenate (D609) involve ceramide and cell cycle inhibition.Mol Neurobiol. 2012 Jun;45(3):455-64. Epub 2012 Mar 14. [Content Brief]

[3]. Lu Zhang, et al. D609 inhibits progression of preexisting atheroma and promotes lesion stability in apolipoprotein e-/- mice: a role of phosphatidylcholine-specific phospholipase in atherosclerosis. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):411-8. [Content Brief]

[4]. Rachele Pandolfi, et al. Role of acid sphingomyelinase and IL-6 as mediators of endotoxin-induced pulmonary vascular dysfunction. Thorax. 2017 May;72(5):460-471. [Content Brief]

[5]. Kalluri HS, et al. D609 inhibits the proliferation of neural progenitor cells.Neuroreport. 2010 Jul 14;21(10):700-3. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	3.7529 mL	18.7645 mL	37.5291 mL	93.8227 mL
H₂O / DMSO	5 mM	0.7506 mL	3.7529 mL	7.5058 mL	18.7645 mL
DMSO	10 mM	0.3753 mL	1.8765 mL	3.7529 mL	9.3823 mL
	15 mM	0.2502 mL	1.2510 mL	2.5019 mL	6.2548 mL
	20 mM	0.1876 mL	0.9382 mL	1.8765 mL	4.6911 mL
	25 mM	0.1501 mL	0.7506 mL	1.5012 mL	3.7529 mL
	30 mM	0.1251 mL	0.6255 mL	1.2510 mL	3.1274 mL
	40 mM	0.0938 mL	0.4691 mL	0.9382 mL	2.3456 mL
	50 mM	0.0751 mL	0.3753 mL	0.7506 mL	1.8765 mL
	60 mM	0.0625 mL	0.3127 mL	0.6255 mL	1.5637 mL
	80 mM	0.0469 mL	0.2346 mL	0.4691 mL	1.1728 mL
	100 mM	0.0375 mL	0.1876 mL	0.3753 mL	0.9382 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

D609

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) D609

Alle Phospholipase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

D609

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Antiviral Compound Library

Lipid Metabolism Compound Library

Targeted Diversity Library

Metabolic Enzyme Compound Library

Highly Selective Inhibitors Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) D609

Alle Phospholipase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (8)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

D609 Related Classifications

HY-70072 Related Classifications